Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases

Table 1

Examples of CO-releasing molecules (CORMs) and their clinical applications. The table was based on Ismailova et al. [138].

Molecule	Clinical applications
CORM-2	Antibacterial activity (E. coli, H. pylori, P. aeruginosa), neuroprotection, cochlear inflammation, neuropathic pain, colitis, bacterial LPS-induced inflammation, TNF-α-induced inflammation, inflammation-induced blood clotting, abnormal platelet coagulation, intestinal mucosa injury, sepsis, hyperglycemia, obesity, cancer (prolonged survival, decreased angiogenesis, and cell aggregation), cardioprotection, kidney transplantation
CORM-3	Antibacterial effect (H. pylori, S. typhimurium, P. aeruginosa), neuroinflammation, periodontal inflammation, septic lung injury, cardioprotection, hemorrhagic shock, cardiac transplantation, renoprotection, postoperative ileus, increased intraocular pressure, anticoagulation, vascular inflammation, pulmonary hypertension
PhotoCORM/TryptoCORM	Antibacterial effect against E. coli, N. gonorrhoeae
CORM-371	Antibacterial effect against P. aeruginosa
CORM-A1	Antibacterial effect against P. aeruginosa, improved neurodifferentiation, diabetes (facilitated beta cell regeneration), obesity, autoimmune uveoretinitis, hemorrhagic shock, liver injury, anticoagulation
ALF186, ALF492	Neuroprotection (ischemic insult, malaria)
CORM-401	Efficient vasodilator
CO-Hbv	Colitis

In vitro studies (cell/tissue cultures). In vivo studies (rodent models).